![]() |
|
|
Vol. 62, Issue 5, 971-974, November 2002
Departments of Medicine and Biochemistry and Howard Hughes Medical Institute, Duke University Medical Center, Durham, North Carolina (R.J.L., K.L.P.); The Geriatrics Research, Education and Clinical Center, Durham Veterans Affairs Medical Center, Durham, North Carolina (L.M.L.)
| |
Article |
|---|
|
|
|---|
In
simpler times, studies of G protein-coupled receptor (GPCR)
signaling focused almost exclusively on pathways characterized by a
small number of sequential events, largely confined to the plasma
membrane [for example, activation of adenylyl cyclase by the
2AR (Lefkowitz, 2000
)]. However, in recent
years, there has been a growing awareness that GPCRs stimulate much
more complex pathways that ultimately connect events at the plasma
membrane to nuclear events, such as gene transcription. Receptor
regulation of mitogen-activated protein kinases is a case in point. The
complexity, heterogeneity, and apparent redundancy of the pathways that
lead from the seven membrane-spanning and tyrosine kinase receptors in
the plasma membrane to ERK in the cytosol are dazzling and involve
almost every known type of signaling molecule (Luttrell et al., 1999
;
Gutkind, 2000
). Moreover, this remarkable multiplicity of pathways
extends to individual receptors. Thus, a single receptor may signal to
ERK by numerous pathways, the importance of which may vary dramatically
between different cell types or cell lines or even among different
isolates of the "same" cell line. Therefore, the very general
conclusions drawn by Friedman et al. (2002)
concerning the "dominant
mechanism for
2AR activation of ERK" in an
article in this issue of Molecular Pharmacology represent a
broad and potentially misleading simplification. However, this article
provides an excellent focal point for discussion of the complexity of
signaling pathways that lead from GPCRs to downstream effectors such as ERK and an occasion to highlight an interesting mechanism for regulating the signaling specificity of such receptors: the
"switching" of their G protein-coupling specificity by PKA-mediated
receptor phosphorylation.
The most thoroughly studied actions of the Gs
coupled
2AR are mediated by cAMP and PKA. The
first Gs-dependent effect of
2ARs on ERK discovered was cAMP-mediated
inhibition of ERK (Cook and McCormick, 1993
; Wu et al.,
1993
; Crespo et al., 1995
). This is due to the
G
s-dependent activation of PKA, leading to
phosphorylation and inhibition of c-Raf1 (Cook and McCormick, 1993
; Wu
et al., 1993
). However, stimulation of the
2AR
can also activate ERK via a Gs dependent pathway
in some cell types. This has been demonstrated in human embryonic
kidney (HEK) 293 cells (Schmitt and Stork, 2000
) and S49 lymphoma cells
(Wan and Huang, 1998
). This pathway is pertussis toxin-insensitive and
seems to involve Src, the small G protein Rap1, and the B-Raf isoform,
rather than c-Raf1. It is independent of Ras. This pathway, originally
described by Schmitt and Stork in 293 cells (Schmitt and Stork, 2000
),
is now recharacterized by Friedman et al. (2002)
.
However, a growing body of in vivo and in vitro data indicate that some
actions of the
2AR are transduced via
Gi. These include activation of the enzymes ERK
(Daaka et al., 1997
), AKT (Zhu et al., 2001
), phosphoinositide-3 kinase
(Zhu et al., 2001
) and certain receptor tyrosine kinases (Maudsley et
al., 2000
), and inhibition of adenylyl cyclase (Lawler et al., 2001
).
Gi-mediated activation of ERK by the
2AR has been demonstrated in cultured HEK293
cells (Daaka et al., 1997
), monkey kidney cells (COS-7) (Maudsley et al., 2000
), Chinese hamster ovary (CHO) cells (Zamah et al., 2002
), and
cultured rat cardiac myocytes (Zou et al., 1999
). This
Gi-mediated pathway is pertussis toxin-sensitive
and seems to be transduced by G
subunits, Src, Ras, and c-Raf1,
and may involve transactivation of the epidermal growth factor receptor
(Daaka et al., 1997
; Luttrell et al., 1999
; Zou et al., 1999
; Gutkind,
2000
; Maudsley et al., 2000
; Lawler et al., 2001
; Zhu et al., 2001
;
Zamah et al., 2002
).
These two pathways are schematically depicted in Fig.
1. A particularly interesting aspect of
the Gi-mediated stimulation of ERK via the
2AR is that it seems to require prior
phosphorylation of the receptor by PKA (Daaka et al., 1997
), a
mechanism previously demonstrated to "desensitize"
2ARs by decreasing their coupling to
Gs (Benovic et al., 1985
; Pitcher et al., 1992
).
PKA phosphorylation simultaneously diminishes
2AR coupling to Gs and
increases coupling to Gi. This mechanism has been
referred to as G protein "switching" (Daaka et al., 1997
). That
some regulatory mechanism would be required to "switch" or alter
the inherent coupling of the
2AR and thus
enable its interaction with Gi was clear, in
retrospect, from reconstitution experiments performed almost 20 years
ago (Cerione et al., 1985
). These demonstrated, in reconstituted
systems consisting only of purified receptors and G proteins, that the
2AR, although coupling robustly to
Gs, was virtually devoid of coupling to
Gi.
|
The first indication that PKA-mediated phosphorylation of the
2AR might do more than simply
"desensitize" the receptor by inhibiting its coupling to
Gs was provided by Okamoto et al. (1991)
. They
demonstrated that a short peptide derived from the third cytoplasmic
loop of the
2AR effectively activated purified
Gs but only very weakly activated
Gi in vitro. This peptide contains one of the two
consensus PKA phosphorylation sites found in the receptor. When the
peptide was phosphorylated by PKA, its ability to activate
Gs was dramatically reduced, whereas its ability
to activate Gi was reciprocally increased.
These results are essentially identical to findings in recent in vitro
reconstitution studies with the intact recombinant human
2AR and recombinant Gs
and Gi (Zamah et al., 2002
). Reconstituted native
2AR mediates robust activation of
Gs but not Gi. When the
receptor is phosphorylated in vitro by PKA, Gs
coupling is reduced, but Gi activation is
markedly enhanced. The results are replicated when a purified
recombinant
2AR, in which the PKA phosphorylation sites are mutated (S
D) to mimic the effects of phosphorylation, is tested in the reconstituted system. Again, Gs coupling is impaired, whereas
Gi stimulation is increased (Zamah et al., 2002
).
That PKA-mediated phosphorylation of the
2AR
might regulate its coupling to Gs and
Gi in cells was first appreciated in
studies performed using a line of HEK293 cells; Daaka et al. (1997)
demonstrated that activation of ERK by endogenous
2ARs was mediated largely by
Gi (pertussis toxin-sensitive). However,
concomitant PKA activation seemed to be required because the ERK
activation was blocked by the PKA inhibitor H89, as was the ability of
the receptor to stimulate [32P]GTP azidoanilido
loading of Gi in cell membranes.
Gi-mediated inhibition of forskolin-stimulated
adenylyl cyclase by the
2AR in HEK293 cells
was also blocked by pertussis toxin or H89 but not by a PKC inhibitor
(Lawler et al., 2001
). That the receptor was the site of the required
PKA phosphorylation was suggested by the failure of a mutant
2AR (S
A), which was not a substrate for
PKA, to activate ERK when transfected into these cells (Daaka et al.,
1997
).
Gi-mediated activation of ERK by the
2AR, which requires prior activation of PKA,
has subsequently been demonstrated in murine submandibular gland cells
(Luo et al., 1999
), rat cardiac myocytes (Zou et al., 1999
), and CHO
cells (Zamah et al., 2002
). Moreover in the latter two systems, as in
the original studies with HEK293 cells, the
2AR itself was implicated as the locus of PKA
phosphorylation, because phosphorylation site mutants of the
2AR (PKA
) failed to
activate ERK or acted as dominant negatives for
isoproterenol-stimulated ERK activation. Recently, evidence has been
presented suggesting that this switching mechanism operates in vivo in
the mouse heart (Hasseldine et al., 2002
).
An entirely analogous switching mechanism has been reported for the
Gs-coupled mouse prostacyclin receptor (Lawler et
al., 2001
). In HEK293 cells, this receptor can activate
Gs (stimulate cAMP accumulation),
Gi (inhibit forskolin stimulated cAMP
accumulation), and Gq (activate phospholipase C
leading to calcium release). However, the Gi- and
Gq-mediated responses are blocked by H89, and a
receptor point mutant (S357A) that cannot undergo PKA phosphorylation activates only Gs. Moreover, whereas the
wild-type receptor can be immunoprecipitated with
Gs, Gi, and
Gq in an agonist-dependent manner, the mutant
receptor interacts only with Gs. Not only do these studies confirm the
Gs-to-Gi switching
mechanism, they extend it to another G protein,
Gq (Lawler et al., 2001
). A further interesting twist is that the human prostacyclin receptor, which has a
PKC site in place of the PKA site of the mouse receptor, couples to Gs and Gq but not
Gi. Substitution of the PKC site by a PKA site by
mutagenesis enables PKA-dependent coupling to Gi,
which is lost on further mutagenesis to remove the relevant serine from this position (Miggin and Kinsella, 2002
). Thus, at present, it seems
that PKA, but not PKC, can mediate such switching phenomena.
The studies reviewed above (summarized in Table
1), provide compelling support for the
idea that PKA-mediated phosphorylation of GPCRs regulates their
coupling to different G proteins, especially Gi.
So why then do Friedman et al. (2002)
fail to observe this switching
mechanism in their 293 cells, a line previously used by others to
demonstrate just such effects for both the
2AR
(Daaka et al., 1997
; Lawler et al., 2001
) and the prostacyclin receptor (Lawler et al., 2001
; Miggin and Kinsella, 2002
)? The most obvious lesson is that transformed cell lines are not uniform in their properties. During prolonged culture, such lines alter chromosome number, gene expression signaling pathways used, and even morphology. Thus, it is not possible to draw from any single study of GPCR-mediated ERK activation in a cultured cell line any valid, generally applicable conclusions about the "dominant pathway of ERK activation" by that
receptor.
|
Lines referred to as HEK293 have a remarkable heterogeneity; for
example, we recently tested the sensitivity to pertussis toxin of ERK
activity stimulated by isoproterenol through endogenous
2ARs in nine different isolates of HEK293
cells and found that this varied from 0 to 100% (Fig.
2). Friedman et al. (2002)
reported a
minimal effect of pertussis toxin on ERK activation by the
2AR, whereas, by contrast, Daaka et al. (1997)
reported that the
2AR-mediated effect on ERK
was quite sensitive to pertussis toxin. Based on these findings, the
divergent effects of a PKA-
2AR
mutant receptor on ERK activity in the different studies are quite
predictable. In the HEK 293 cells used by Friedman et al. (2002)
, the
2AR activates ERK almost exclusively via
Gs. Because such signaling is inhibited by PKA
phosphorylation of the receptor (Fig. 1), the
PKA-
2AR should be normally active
or superactive in these cells. Conversely, in the cells used by Daaka
et al. (1997)
, the
2AR activates ERK primarily
via Gi. Because such signaling is enabled by
receptor phosphorylation (Fig. 1), the
PKA-
2AR should be inactive in
these cells. This is precisely what was found in the two studies (Daaka
et al., 1997
; Friedman et al., 2002
).
|
Currently unclear, however, are the specific differences that account for the marked variability in pathway usage between these different isolates of 293 cells. This largely unstudied problem may hold clues to understanding important aspects of cellular regulation. Recently developed gene chip array and proteomics approaches have obvious applicability here, as do more specific, hypothesis-driven approaches focusing on expression levels of the obvious known intermediates in the various pathways. Moreover, to understand the ultimate physiological outcome, the relative contributions of each of the different pathways need to be characterized both in primary cells and in vivo.
In conclusion, the article by Friedman et al. (2002)
illustrates the
confusions of interpretation that result from failing to appreciate the
diversity and complexity of mechanisms that can be used by a single
receptor to signal to a very downstream effector in different cells. In
a final ironic twist, the pathway globally assigned by Friedman et al.
as "the dominant pathway for
2AR
activation of ERK" (Gs
AC
PKA
Src 
Rap1 

ERK) has recently been shown to
inhibit Ras-dependent ERK activity in NIH3T3 fibroblasts
(Schmitt and Stork, 2002
), thereby inhibiting cell growth.
| |
Acknowledgments |
|---|
We thank Musa Zamah, Seungkirl Ahn, and Darrell Capel for help with experiments.
| |
Footnotes |
|---|
Received August 1, 2002; Accepted August 6, 2002
This work was supported in part by National Institutes of Health grant HL16037. R.J.L. is an Investigator of the Howard Hughes Medical Institute.
Address correspondence to: Dr. Robert J. Lefkowitz, Howard Hughes Medical Institute, Duke University Medical Center, Durham, NC 27710. E-mail: lefko001{at}receptor-biol.duke.edu
| |
Abbreviations |
|---|
GPCR, G protein-coupled receptor; AR, adrenergic receptor; ERK, extracellular signal-regulated kinase; HEK, human embryonic kidney; PKC, protein kinase C.
| |
References |
|---|
|
|
|---|

-dependent activation and a G
s-cAMP-mediated inhibition.
J Biol Chem
270:
25259-65
2-Adrenergic receptor lacking the protein kinase A consensus sites fully activates extracellular signal-regulated kinase 1/2 in human embryonic kidney 293 cells: lack of evidence for Gs/Gi switching.
Mol Pharmacol
62:
1094-1102
2-adrenoceptors (
2AR) in mice (TG4) exposes pleiotropy in G protein coupling.
Pharmacologist
44(Suppl. 1):
A199.
2-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor.
J Biol Chem
275:
9572-9580
2-adrenergic receptor activates extracellular signal-regulated kinases (ERKs) via the small G protein rap1 and the serine/threonine kinase B-Raf.
J Biol Chem
275:
25342-50
2-adrenergic receptor regulates its coupling to Gs and Gi. Demonstration in a reconstituted system.
J Biol Chem
277:
31249-31256
2-adrenergic signaling in adult mouse cardiac myocytes.
Proc Natl Acad Sci USA
98:
1607-1612This article has been cited by other articles:
![]() |
A. Hu, G. Nino, J. S. Grunstein, S. Fatma, and M. M. Grunstein Prolonged heterologous {beta}2-adrenoceptor desensitization promotes proasthmatic airway smooth muscle function via PKA/ERK1/2-mediated phosphodiesterase-4 induction Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1055 - L1067. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Maillet, N. Pellegrini, C. Valant, B. Bucher, M. Hibert, J.-J. Bourguignon, and J.-L. Galzi A novel, conformation-specific allosteric inhibitor of the tachykinin NK2 receptor (NK2R) with functionally selective properties FASEB J, July 1, 2007; 21(9): 2124 - 2134. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. Goddard III and R. Abrol 3-Dimensional Structures of G Protein-Coupled Receptors and Binding Sites of Agonists and Antagonists J. Nutr., June 1, 2007; 137(6): 1528S - 1538S. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Houslay, G. S. Baillie, and D. H. Maurice cAMP-Specific Phosphodiesterase-4 Enzymes in the Cardiovascular System: A Molecular Toolbox for Generating Compartmentalized cAMP Signaling Circ. Res., April 13, 2007; 100(7): 950 - 966. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ma and G. Pei beta-arrestin signaling and regulation of transcription J. Cell Sci., January 15, 2007; 120(2): 213 - 218. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. E. Schutzer, H. Xue, J. F. Reed, and S. L. Mader Effect of Age on Vascular {beta}2-Adrenergic Receptor Desensitization Is Not Mediated by the Receptor Coupling to G{alpha}i Proteins. J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2006; 61(9): 899 - 906. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Smith and L. M. Luttrell Signal Switching, Crosstalk, and Arrestin Scaffolds: Novel G Protein-Coupled Receptor Signaling in Cardiovascular Disease Hypertension, August 1, 2006; 48(2): 173 - 179. [Full Text] [PDF] |
||||
![]() |
S. K. Shenoy, M. T. Drake, C. D. Nelson, D. A. Houtz, K. Xiao, S. Madabushi, E. Reiter, R. T. Premont, O. Lichtarge, and R. J. Lefkowitz beta-Arrestin-dependent, G Protein-independent ERK1/2 Activation by the beta2 Adrenergic Receptor J. Biol. Chem., January 13, 2006; 281(2): 1261 - 1273. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Lynch, G. S. Baillie, A. Mohamed, X. Li, C. Maisonneuve, E. Klussmann, G. van Heeke, and M. D. Houslay RNA Silencing Identifies PDE4D5 as the Functionally Relevant cAMP Phosphodiesterase Interacting with {beta}Arrestin to Control the Protein Kinase A/AKAP79-mediated Switching of the {beta}2-Adrenergic Receptor to Activation of ERK in HEK293B2 Cells J. Biol. Chem., September 30, 2005; 280(39): 33178 - 33189. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Seck, M. Pellegrini, A. M. Florea, V. Grignoux, R. Baron, D. F. Mierke, and W. C. Horne The {Delta}e13 Isoform of the Calcitonin Receptor Forms a Six-Transmembrane Domain Receptor with Dominant-Negative Effects on Receptor Surface Expression and Signaling Mol. Endocrinol., August 1, 2005; 19(8): 2132 - 2144. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Nasrallah and R. L. Hebert Prostacyclin signaling in the kidney: implications for health and disease Am J Physiol Renal Physiol, August 1, 2005; 289(2): F235 - F246. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Barthet, F. Gaven, B. Framery, K. Shinjo, T. Nakamura, S. Claeysen, J. Bockaert, and A. Dumuis Uncoupling and Endocytosis of 5-Hydroxytryptamine 4 Receptors: DISTINCT MOLECULAR EVENTS WITH DIFFERENT GRK2 REQUIREMENTS J. Biol. Chem., July 29, 2005; 280(30): 27924 - 27934. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-K. Yeh, P. M. Ghosh, H. Dang, Q. Liu, A. L. Lin, B.-X. Zhang, and M. S. Katz {beta}-Adrenergic-responsive activation of extracellular signal-regulated protein kinases in salivary cells: role of epidermal growth factor receptor and cAMP Am J Physiol Cell Physiol, June 1, 2005; 288(6): C1357 - C1366. [Abstract] [Full Text] [PDF] |
||||
![]() |
V.-P. Jaakola, J. Prilusky, J. L. Sussman, and A. Goldman G protein-coupled receptors show unusual patterns of intrinsic unfolding Protein Eng. Des. Sel., February 1, 2005; 18(2): 103 - 110. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Fan, P. M. Bryan, L. K. Antos, R. J. Potthast, and L. R. Potter Down-Regulation Does Not Mediate Natriuretic Peptide-Dependent Desensitization of Natriuretic Peptide Receptor (NPR)-A or NPR-B: Guanylyl Cyclase-Linked Natriuretic Peptide Receptors Do Not Internalize Mol. Pharmacol., January 1, 2005; 67(1): 174 - 183. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Keiper, M. B. Stope, D. Szatkowski, A. Bohm, K. Tysack, F. vom Dorp, O. Saur, P. A. Oude Weernink, S. Evellin, K. H. Jakobs, et al. Epac- and Ca2+-controlled Activation of Ras and Extracellular Signal-regulated Kinases by Gs-coupled Receptors J. Biol. Chem., November 5, 2004; 279(45): 46497 - 46508. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Beom, D. Cheong, G. Torres, M. G. Caron, and K.-M. Kim Comparative Studies of Molecular Mechanisms of Dopamine D2 and D3 Receptors for the Activation of Extracellular Signal-regulated Kinase J. Biol. Chem., July 2, 2004; 279(27): 28304 - 28314. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Breit, M. Lagace, and M. Bouvier Hetero-oligomerization between {beta}2- and {beta}3-Adrenergic Receptors Generates a {beta}-Adrenergic Signaling Unit with Distinct Functional Properties J. Biol. Chem., July 2, 2004; 279(27): 28756 - 28765. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Iacovelli, L. Capobianco, M. Iula, V. Di Giorgi Gerevini, A. Picascia, J. Blahos, D. Melchiorri, F. Nicoletti, and A. De Blasi Regulation of mGlu4 Metabotropic Glutamate Receptor Signaling by Type-2 G-Protein Coupled Receptor Kinase (GRK2) Mol. Pharmacol., May 1, 2004; 65(5): 1103 - 1110. [Abstract] [Full Text] |
||||
![]() |
S. L. Kirstein and P. A. Insel Autonomic Nervous System Pharmacogenomics: A Progress Report Pharmacol. Rev., March 1, 2004; 56(1): 31 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. B. Bolger, A. McCahill, E. Huston, Y.-F. Cheung, T. McSorley, G. S. Baillie, and M. D. Houslay The Unique Amino-terminal Region of the PDE4D5 cAMP Phosphodiesterase Isoform Confers Preferential Interaction with {beta}-Arrestins J. Biol. Chem., December 5, 2003; 278(49): 49230 - 49238. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Baker, I. P. Hall, and S. J. Hill Agonist and Inverse Agonist Actions of {beta}-Blockers at the Human {beta}2-Adrenoceptor Provide Evidence for Agonist-Directed Signaling Mol. Pharmacol., December 1, 2003; 64(6): 1357 - 1369. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Ally, K. L. Ives, E. Traube, I. Eltounsi, P.-W. Chen, P. J. Cahill, J. F. Battey, M. R. Hellmich, and G. S. Kroog Agonist- and Protein Kinase C-Induced Phosphorylation Have Similar Functional Consequences for Gastrin-Releasing Peptide Receptor Signaling via Gq Mol. Pharmacol., October 1, 2003; 64(4): 890 - 904. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Baillie, A. Sood, I. McPhee, I. Gall, S. J. Perry, R. J. Lefkowitz, and M. D. Houslay beta -Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta -adrenoceptor switching from Gs to Gi PNAS, February 4, 2003; 100(3): 940 - 945. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||